MNTR Stock News 2.1000 05/08/2014 13:48:59 Mentor Capital Inc.

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Mentor Capital Inc. (MNTR) 2.1000 $MNTR

Mentor Capital Team Adds AZ to its Marijuana Edibles Footprint
Business Wire - Fri Apr 18, 3:30PM CDT
Mentor Capital, Inc. (OTC Markets: MNTR) announced that its shareholder's medical marijuana and cannabis business interests have again expanded to another state to now include Arizona.

Mentor Capital Flagship Bhang Opens CBD Line at Cannabis Cup
Business Wire - Wed Apr 16, 11:19AM CDT
Mentor Capital, Inc. (OTC Markets: MNTR) announced that its flagship portfolio company, Bhang Chocolate Company, Inc., will be premiering its newest line of High CBD products at this weekend's High Times Cannabis Cup in Denver. Starting with Bhang's 10mg and 25mg gum line, these products, will be available through traditional retailers in addition to dispensaries at the end of April. Bhang worked in coordination with PureCBD, Inc., to deliver a product that preserves the medically oriented benefits of CBD, but may be legally sold directly by Bhang because of the very low THC levels in its sourcing.

Cannabis Sector Advances Cautiously - Company's CEO Discusses 1st Quarter Financials
PR Newswire - Mon Apr 14, 8:05AM CDT
Marijuana companies aim to move forward after sector stabilizes: The CannaBusiness Group, Inc. (OTC: CBGI), Mentor Capital, Inc. (OTC: MNTR), Tranzbyte Corporation (OTC: ERBB), Alternative Fuels Americas, Inc. (OTC: AFAI) and Nuvilex, Inc. (OTC: NVLX)

Wells Fargo & Company's First Quarter Earnings Hits Record; H&R Block Signs Deal with BofI Federal Bank
ACCESSWIRE - Sun Apr 13, 11:35PM CDT
Wells Fargo & Company (NYSE: WFC) - For an in-depth report on Wells Fargo & Company follow: www.BullTrends.com/stockquote/WFC

Mentor Capital Qualifies for Highest Segment of OTC Pink Market
Business Wire - Fri Apr 11, 11:51AM CDT
Mentor Capital, Inc. (OTC Markets: MNTR) status was upgraded today by OTC Markets Group to the highest of the three primary OTC Pink Marketplace segments: Current Information. All updated Mentor Capital financials, filings, disclosures and legal opinions through February 28, 2014, are publicly available on the OTC Disclosure & News Service pursuant to its guidelines. This is a first part in the active execution of the company's stated goal to step up to current status, complete audits, voluntarily file a Form 10, move up quickly to the OTCQB and then onto NASDAQ. At each stage along the way, companies historically have experienced greater institutional participation, liquidity, coverage and visibility for shareholders.

Mentor Capital Targets $100 Million for Marijuana Investments from Call of Series D Warrants
Business Wire - Wed Mar 12, 11:49AM CDT
Mentor Capital, Inc. (OTC Markets: MNTR) announced that it is Calling its 15 Million Series D ($7) warrants at their long-standing strike price of $7.00 per share, and in this fashion targets to raise $100 Million for marijuana related investments. These warrants are already in the hands of Mentor Capital's original 1,500 mostly accredited investors. The call period is through June 30th, 2014.

Mentor Capital Acquires 60% of Bhang Chocolate for $39 Million
Business Wire - Tue Mar 11, 11:11AM CDT
Mentor Capital, Inc. (OTC Markets: MNTR) announced today that it has been selected by Bhang Chocolate Company, Inc. to provide $39 Million in equity funding for Bhang's national and international expansion and to help further extend their market-leading brand across the marijuana related sector. Mentor Capital CEO, Chet Billingsley, affirms, "By a wide margin, five time cannabis cup winner, Bhang Chocolate is recognized as the world's singular leading cannabis brand. We feel privileged to be working with the Bhang management team lead by founder Scott Van Rixel. In the explosively growing and sometimes chaotic environment accompanying marijuana legalization, they provide a bulwark of business professionalism and integrity in the delivery of Bhang's gourmet medicinal chocolates and growing infused edible selections."

WEALTHMAKERS.COM Issues Report on Mentor Capital
M2 - Mon Mar 10, 8:54AM CDT
March 10, 2014 / M2 PRESSWIRE / WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued a new research report today on Mentor Capital (OTC: MNTR). The report highlights the short term bullish pattern that has emerged, the SqueezeTrigger Price of $2.54 and the projected short squeeze price target of $19.59 per share.

Mentor Capital Catches Market Makers Selling 250% of Shares
Marketwire - Tue Feb 25, 11:50AM CST
Mentor Capital, Inc. (OTC Pink: MNTR) announces that BuyIns.Net has uncovered that Shorts have sold 5.5 Million of the 2.2 Million (sic.) Mentor Capital, Inc. shares in the float and available to trade. In response to this situation, Mentor Capital Inc.'s CEO, Chet Billingsley comments, "For 2014 we retained BuyIns.Net, who monitors all stock trades for illegal short selling activity, soon after 50% of our float suspiciously traded in two hours." According to his web site, BuyIns.Net founder, Tom Ronk, entered into a business partnership with former SEC Chairman, Harvey Pitt. They spearheaded the passage of Regulation SHO that, if followed, helps safeguard public companies from these sorts of short selling issues.

BUYINS.NET Issues Mentor Capital SqueezeTrigger Report
M2 - Tue Feb 25, 2:34AM CST
BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on Mentor Capital (OTC: MNTR) after releasing the latest short sale data through February 21, 2014. The total aggregate number of shares shorted since August 2009 is approximately 3.45 million shares. Approximately 41.09% of daily trading volume is short selling. The SqueezeTrigger price for all MNTR shares shorted is $1.53. A short squeeze has just begun as shares of MNTR closed above the $1.53 SqueezeTrigger price.

Mentor Capital Acquires 51% Stake in MicroCannaBiz, LLC
Business Wire - Thu Feb 20, 12:54PM CST
Mentor Capital, Inc. (OTC Markets: MNTR) announced today that it has acquired a 51% equity interest in MicroCannaBiz, LLC, which was recently formed to address the legal cannabis market by Financial Research Solutions, Inc., a media, microcap investment research and educational training company.

Mentor Capital Agrees to $2M Backing for Cannabis Advocacy Business
Business Wire - Mon Jan 27, 7:30AM CST
Mentor Capital, Inc. (OTC Markets: MNTR) announced that it has agreed to provide $2 Million in funding for The Cannabis Advocacy Machine. Mentor Capital CEO, Chester Billingsley, explains that behind any political initiative there is a commercial enterprise in the business of developing data and statistics, directing advertisement, and maintaining proprietary software systems. The Cannabis Advocacy Machine, a division of The Machine Corporation, is providing Moneyball-like direction and support that is key to that process for the legalization of cannabis across the country. "Signing a letter of intent for 20% of The Machine Corporation under the nationally experienced leadership of the first tier team with Joe Brezny, aims to accelerate the legislative initiatives critical to the lifting of marijuana prohibition, in what may be a surprisingly profitable manner."

Mentor Capital Cannabis Index Up 325% in First Three Weeks of 2014
Business Wire - Wed Jan 22, 10:25AM CST
Mentor Capital, Inc. (OTCMKTS:MNTR) reports that its proprietary Cannabis Index appreciated 325% during the first three weeks of 2014. The overall positive and profitable experience for marijuana based businesses and taxing authorities alike is thought to be a key driver in this sector-wide advance.

Mentor Capital Cancer Immunotherapy Index Up 97% in 2013
Business Wire - Tue Jan 21, 10:01AM CST
Mentor Capital, Inc. (OTCMKTS:MNTR) reports that its proprietary Cancer Immunotherapy Index appreciated 97.4% during 2013. The equally weighted Cancer Immunotherapy Index is regularly benchmarked against the appreciation of the average of the NASDAQ, S&P, and NYSE Biotech Indices. For the same 2013 annual period the biotech indices averaged a 54.8% gain.

Mentor Capital Says HempCon to be First Funded from New Public Cannabis Fund
Business Wire - Fri Jan 17, 12:40PM CST
Mentor Capital, Inc. (OTC Markets:MNTR) announced its first major acquisition for cannabis funding will be HempCon, Inc. That medical marijuana convention company is hosting hemp industry pioneers at the San Jose Convention Center January 17-19th. The agreement by principals and letter of intent outlines that HempCon, Inc. will receive $7.0 Million from Mentor Capital investors plus future public market appreciation for a 100% interest. Positioning HempCon to be the first to be funded by the first operating public cannabis fund of its kind should be wholly credited to savvy action by HempCon founder Edwin Kwong, who had already been approached by two other public companies, reports Mentor Capital CEO Chester Billingsley.

Mentor Capital Negotiates to Fund Eighteen Leading Cannabis Brands
Business Wire - Wed Nov 13, 9:43AM CST
Mentor Capital, Inc. (Pink Sheets:MNTR) reports that it has entered into negotiations to fund eighteen legal cannabis related companies. These companies are variously described in writing by their fellow CEO's as the "cream of the crop," "great, " "the best... I have ever seen" and that "their Cannabis Cup awards speak for themselves." While not every one of the CEO's in negotiations will finally join Mentor Capital, the offers are generally what management has already verbally agreed to.

Mentor Capital, Inc. Funds Completion of 12.5% Stock Buyback
Business Wire - Thu Sep 05, 1:56PM CDT
Mentor Capital, Inc. (OTCMKTS:MNTR) has deposited funds with its broker to complete the final tranche of its multi-year stock repurchase program. In 2008, Mentor Capital, Inc. committed to the repurchase of 12.5% of its then outstanding common stock and is positioned to wrap-up that stock buy-back now.

Mentor Capital Cancer Immunotherapy Index Gains 31% During First Half of 2013
Business Wire - Fri Jul 19, 12:49PM CDT
Mentor Capital, Inc. (Pink Sheets:MNTR) reports that its proprietary Cancer Immunotherapy Index appreciated 30.6% during the first half of 2013. The equally weighted Cancer Immunotherapy Index is regularly benchmarked against the appreciation of the average of the NASDAQ, S&P, and NYSE Biotech Indices. For the first half the biotech indices averaged a 34.5% gain.

Mentor Capital Cancer Immunotherapy Index Gains 32% YTD and Adds Second Generation Firms for 2013
Business Wire - Fri Mar 15, 11:51AM CDT
Mentor Capital, Inc. (Pink Sheets:MNTR) reports that for 2013 it has added Galena Biopharma Corporation (NASDAQ:GALE), NewLink Genetics Corporation (NASDAQ:NLNK), Vical Incorporated (NASDAQ:VICL) and Inovio Pharmaceuticals, Inc. (NYSE MKT:INO) to its proprietary Cancer Immunotherapy Index. The four firms and others in the Index represent the second generation immunotherapy knowledge that has evolved since 2009 when Mentor Capital first published.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bio-Thera's New Data: A Game Changer for NSCLC?

Updated Category News Views 214

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...

Continue Reading
Amgen's IMDELLTRA® Shows Promise in SCLC Battle

Updated Category News Views 292

Breakthrough Results in SCLC Treatment For years, small cell lung cancer (SCLC) has been the unruly beast in the oncology world, defying treatment advances and keeping survival rates stubbornly low. This nasty foe might just have met its match, folks. Amgen (NASDAQ:AMGN) announced results from their Phase 3 DeLLphi-305 trial that show their drug IMDELLTRA®, when teamed...

Continue Reading
Swanson Nexus Pro Launch: Boost for Dietitians

Updated Category News Views 160

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Continue Reading
CapCut's AI Tools Reshape Video Content Creation

Updated Category News Views 81

AI Revolution in Marketing Content: CapCut Takes Lead It's like the old guard of marketing has hitched a ride on a rocket. In 2026, CapCut has stomped into the limelight with Better Business Advice giving them a nod for their prowess in AI-driven content creation. This isn't some passing trend; it's a seismic shift in how businesses craft their messages. CapCut ain't just...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 25

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
Taiwan Fuses Ancient TCM with Modern Bio Tech in 2026

Updated Category News Views 106

The Dynamic Fusion of Heritage and Innovation When you think about it, mixing centuries-old herbal wisdom with today's cutting-edge biotech might sound like a plot twist, but that's exactly what's cooking in Taiwan. Over at SupplySide Global 2026 in Las Vegas, Taiwan's got something more than just traditional medicine to flaunt; it's showcasing an impressive fusion of...

Continue Reading
York Space Systems Class Action: Deadline Approaches

Updated Category News Views 135

Rapid Deadline: October 30 Looms for York Space Systems You blink, and you might miss the deadline. We’re just a step away from deadline day in the York Space Systems’ class action lawsuit. If you've got skin in this game, time's not on your side. Shareholders, particularly those who hopped on the York Space train via their IPO back in January 2026, are staring down...

Continue Reading
Survivors Secure $800M Settlement with NY Archdiocese

Updated Category News Views 116

Massive Settlement: A Long-Awaited Justice Here's a different kind of news that's hitting like a thunderbolt. Over 1,300 survivors of abuse have finally struck a landmark deal with the Archdiocese of New York. Not only are the numbers staggering, but the relief for these individuals is palpable. We're talking about more than $800 million on the table here. That's some...

Continue Reading
Hims & Hers Faces Securities Lawsuit Amid Stock Dive

Updated Category News Views 191

Hims & Hers Takes a Hit Right out of the gate, we're seeing Hims & Hers Health, Inc. (NYSE:HIMS) embroiled in a securities class action, thanks to some good old-fashioned alleged corporate shenanigans. It's one of those times where you'd cock an eyebrow and say, "What in the world were they thinking?" The FTC has slapped them with accusations of misleading privacy claims...

Continue Reading
Honeywell Aerospace Faces Class Action: Deadline Looms

Updated Category News Views 93

Navigating the Legal Storm with Honeywell Look, investors never have it easy, and when lawsuits start flying like today's news about Honeywell Aerospace, you better have your wits about you. Now here comes Kahn Swick & Foti, LLC, ringing the alarm bells. Any holders of Honeywell Aerospace stocks between late June and early September of '26 are squarely in the spotlight....

Continue Reading

Top 5 Most Recently Viewed Articles

Beijing's EV Export Rules Impact NIO and Li Auto Stocks

Updated Category News Views 298

Beijing Implements Stricter EV Export Regulations Affecting Stocks Recently, Chinese electric vehicle (EV) stocks NIO (NYSE: NIO) and Li Auto (NASDAQ: LI) have experienced a notable decline following announcements regarding new regulations by Beijing aimed at tightening the export of EVs. New Export Permit Requirements Effective from January 1, the Ministry of Commerce in...

Continue Reading
OceanaGold Set to Announce Q2 2025 Financial Results Soon

Updated Category News Views 122

Upcoming Financial Results from OceanaGold OceanaGold Corporation (TSX: OGC, OTCQX: OCAND) is gearing up to release its operational and financial results for the second quarter of 2025. This detailed announcement will take place after the market close, and it’s expected to shed light on the company's recent performance and highlight future prospects. Conference Call...

Continue Reading
India's July Industrial Growth Surpasses Expectations by 0.1%

Updated Category News Views 121

India's Industrial Output Shows Promising Growth in July Recent government data reveals that India's industrial output rose by a noteworthy 4.8% year-on-year in July. This figure has drawn attention since it slightly exceeds economists' forecast of 4.7% for the same month. These growing numbers reflect a resilient manufacturing sector that is steadily recovering....

Continue Reading
VideoAmp Extends Partnership with Paramount Global for Measurement

Updated Category News Views 180

VideoAmp and Paramount Global Strengthen Their Collaboration VideoAmp, a pioneering media measurement company, has recently announced the continuation of its long-term collaboration with Paramount Global. This partnership reflects a commitment to evolving the advertising landscape with precise audience insights. Comprehensive Audience Measurement This renewal provides...

Continue Reading
Empire State Realty Trust Delivers Strong Q3 Performance and Guidance

Updated Category News Views 53

Empire State Realty Trust Shows Remarkable Q3 Financial Results Empire State Realty Trust (NYSE: ESRT) demonstrated impressive financial outcomes in its most recent earnings call for the third quarter of 2024, surpassing analyst expectations significantly. The real estate investment trust revealed a Funds From Operations (FFO) totaling $69 million, translating to $0.26...

Continue Reading